When you're diving into the world of regulatory submissions, especially for marketing authorization and post-authorization applications, understanding where to find specific information is key. It's a bit like navigating a well-organized library; you need to know which section holds the treasures you're looking for.
For those of you working with the eCTD (electronic Common Technical Document) system, particularly under the guidance for the MHRA (Medicines and Healthcare products Regulatory Agency) in the UK, the question often arises: 'Where exactly does the post-marketing experience get documented?'
While the eCTD structure is designed to be comprehensive, with Modules 1 through 5 covering various aspects of a drug application, the specific details of post-marketing experience aren't confined to a single, isolated section labeled 'Post-Marketing Experience.' Instead, it's woven into the fabric of the submission, primarily within Module 2 and Module 5.
Think of Module 2 as the summary and overview section. Here, you'll find the Clinical Overview and the Summary of Clinical Safety. These sections are crucial for understanding the drug's safety profile as it has evolved, including data gathered after the initial approval. The Summary of Clinical Safety, in particular, will often synthesize information from post-marketing surveillance and studies.
Then, there's Module 5, which is dedicated to Clinical Study Reports. This is where the raw data and detailed reports of clinical studies reside. If post-marketing studies have been conducted – perhaps to investigate a specific safety signal or to gather more data on long-term efficacy – the reports and associated data would be found here. This is where you'd see the evidence supporting any updates or changes to the drug's labeling or usage recommendations based on real-world experience.
It's also worth noting that certain aspects related to pharmacovigilance and risk management plans, which are intrinsically linked to post-marketing activities, are often detailed within Module 1 (specifically in sections related to administrative information and UK-specific requirements) and can be referenced or summarized in Module 2. For instance, the reference material mentions including information about differences in the proposed UK Risk Management Plan (RMP) compared to the RMP approved by a Reference Regulator, and this would be detailed in Module 1 or referenced from there.
So, while there isn't one single folder explicitly named 'Post-Marketing Experience,' the insights you seek are most likely to be found by carefully examining the summaries in Module 2 and the detailed study reports in Module 5, with supporting administrative and risk management information in Module 1.
